GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Cyclically Adjusted Price-to-FCF

Valneva SE (LTS:0OB3) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Valneva SE Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Valneva SE Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Valneva SE's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cyclically Adjusted Price-to-FCF Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 341.62 2,428.61 - -

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Valneva SE's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Valneva SE's Cyclically Adjusted Price-to-FCF falls into.



Valneva SE Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Valneva SE's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Valneva SE's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.229/119.4700*119.4700
=-0.229

Current CPI (Mar. 2024) = 119.4700.

Valneva SE Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.019 100.180 0.023
201409 0.002 99.920 0.002
201412 -0.149 99.860 -0.178
201503 -0.152 100.170 -0.181
201506 -0.023 100.440 -0.027
201509 -0.074 99.950 -0.088
201512 -0.063 100.040 -0.075
201603 -0.098 100.020 -0.117
201606 0.133 100.630 0.158
201609 0.043 100.340 0.051
201612 -0.046 100.650 -0.055
201703 0.133 101.170 0.157
201706 0.033 101.320 0.039
201709 0.014 101.330 0.017
201712 -0.085 101.850 -0.100
201803 0.055 102.750 0.064
201806 0.106 103.370 0.123
201809 -0.035 103.560 -0.040
201812 0.038 103.470 0.044
201903 0.046 103.890 0.053
201906 0.079 104.580 0.090
201909 -0.150 104.500 -0.171
201912 -0.018 104.980 -0.020
202003 0.026 104.590 0.030
202006 1.198 104.790 1.366
202009 -0.476 104.550 -0.544
202012 0.531 104.960 0.604
202103 0.332 105.750 0.375
202106 0.140 106.340 0.157
202109 -0.747 106.810 -0.836
202112 0.178 107.850 0.197
202203 -0.335 110.490 -0.362
202206 -0.736 112.550 -0.781
202209 -0.904 112.740 -0.958
202212 -0.451 114.160 -0.472
202303 -0.202 116.790 -0.207
202306 -0.315 117.650 -0.320
202309 -0.537 118.260 -0.542
202312 -0.517 118.390 -0.522
202403 -0.229 119.470 -0.229

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Valneva SE  (LTS:0OB3) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Valneva SE Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (LTS:0OB3) Business Description

Industry
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (LTS:0OB3) Headlines

No Headlines